Treatment of T-Cell (T-Lineage) Acute Lymphoblastic Leukemia
T-cell acute lymphoblastic leukemia (T-ALL) is a subtype of ALL with a defined treatment approach. This protocol outlines the recommended management for patients with T-lineage disease.
Clinical scenario
T-cell (T-lineage) ALL accounts for approximately 25% of adult ALL cases. Treatment is broadly similar to the approach used for B-lineage ALL, with specific considerations at the consolidation stage for this subtype.
Treatment approach — partial overview
Consolidation therapy for T-cell ALL incorporates nelarabine, and participation in nelarabine-based clinical trials is strongly recommended. The full regimen, sequencing, and decision criteria are available in the complete protocol.
References
DOI: 10.1182/blood.2023023568
- T-ALL comprises 25% of adult ALL and treatment is similar to that for B-LIN ALL.
- The GMALL 08/2013 trial added 2 cycles of nelarabine in standard-risk ALL and reported excellent outcome; the exact role of nelarabine in this intensive pediatric-based regimen remains to be defined.
- It is recommended to participate in nelarabine-based trials whenever possible and until more robust data are available.
View source ↗